From the Science Policy Blog

摘要

The most controversial patents in biotechnology-covering breast cancer genes BRCA1 and BRCA2-rnwere declared invalid this week by a U.S. district court.rnCold Spring Harbor Laboratory has sued its law firm, claiming that the patent application it submitted for discoveries in RNA interference contains "extensive portions" of material from another scientist's patent application.